Bayer AG (BAYGn.DE)
98.93EUR
9:47am BST
€0.14 (+0.14%)
€98.79
€98.80
€99.09
€98.33
288,014
2,972,104
€123.90
€88.81
Latest Key Developments (Source: Significant Developments)
Bayer Says Benefit/Risk Profile Of Essure Has Not Changed & Remains Positive
April 9 (Reuters) - Bayer AG
U.S. FDA Says Issued Order To Restrict Sale & Distribution Of Bayer's Essure Device
April 9 (Reuters) - U.S. Food And Drug Administration::U.S. FOOD AND DRUG ADMINISTRATION SAYS ISSUED AN ORDER TO RESTRICT THE SALE AND DISTRIBUTION OF BAYER'S ESSURE DEVICE.NEW ESSURE LABELING RESTRICTS SALE TO HEALTH CARE PROVIDERS, FACILITIES THAT PROVIDE INFORMATION TO PATIENTS ABOUT RISKS, BENEFITS OF DEVICE.DETERMINED THAT SOME WOMEN STILL ARE NOT RECEIVING INFORMATION ABOUT THE KNOWN RISKS OF ESSURE BEFORE IMPLANTATION. Full Article
Bayer Issues Voluntary Recall Of Alka-Seltzer Plus Products Due To Labelling Error
March 15 (Reuters) - Bayer Ag
Monsanto Q1 Earnings Per Share $0.38
Jan 4 (Reuters) - Monsanto Co
Bayer Announces Initiation Of Rolling Submission Of NDA In U.S. For Larotrectinib
Dec 20 (Reuters) - BAYER AG
Bayer's Rivaroxaban Submitted To U.S. FDA For Approval
Dec 11 (Reuters) - BAYER AG
Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program
Nov 24 (Reuters) - Nektar Therapeutics
Peptidream announces discovery collaboration agreement with Bayer
Nov 19 (Reuters) - Peptidream Inc <4587.T>:Peptidream announces discovery collaboration agreement with bayer.Entered into a multi-target discovery collaboration with Germany-based Bayer AG.Under terms , co would receive undisclosed upfront payment and research funding.Under terms, co is eligible to receive preclinical, clinical, commercialization milestone payments totaling up to $1.11 billion.Also eligible to receive royalties on sales of any products that arise from collaboration. Full Article
PeptiDream announces discovery collaboration agreement with Bayer AG
Nov 16 (Reuters) - PeptiDream Inc <4587.T>:Says it announced today that it has entered into a multi-target discovery collaboration with Germany-based Bayer AG.Under the terms of the agreement, it would receive an undisclosed upfront payment and research funding and is eligible to receive preclinical, clinical, and commercialization milestone payments potentially totaling up to $1.11 billion (124.5 billion yen) .In addition, it is eligible to receive royalties on sales of any products that arise from the collaboration . Full Article
Bayer may terminate Loxo agreement if Larotrectinib is unapproved
Nov 14 (Reuters) - Loxo Oncology
EU mergers and takeovers (April 23)
BRUSSELS, April 23 The following are mergers under review by the European Commission and a brief guide to the EU merger process: